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While dementia is defined as cognitive decline leading to functional impairment, 1 
behaviours and psychological symptoms (BPSD; also referred to as ‘neuropsychiatric 2 
symptoms’, ‘changed behaviours’, ‘behavioural and psychological symptoms of 3 
dementia’, ‘responsive behaviours’; see Cunningham and colleagues)1 which become 4 
almost universal as dementia becomes more severe, often cause more distress to 5 
people with dementia and their families and account for much of the cost (see Lancet 6 
commission).2 Symptoms comprise aggression, agitation, anxiety, apathy, 7 
depression, disinhibited behaviours, nocturnal disruption, psychotic symptoms, vocally 8 
disruptive behaviours, and wandering. 9 
 10 
These behaviours and symptoms impose a large financial burden, as they cause 11 
family and carer partner distress, which also predicts early care home admission,3,4 12 
higher use of emergency department5 and other health facilities;6 as well as requiring 13 
direct care7,8 in care facilities and the community.9 14 
 15 
Behaviours and psychological symptoms are a key driver of the rapidly escalating 16 
social and economic costs of dementia globally. This paper poses the question: Do 17 
the economic benefits of non–pharmacological approaches in preventing and 18 
managing BPSD outweigh the costs?   19 
 20 
The rising prevalence of dementia (currently 50 million people worldwide, estimated 21 
to reach 82 million by 2030 and 152 million by 2050; www.alz.co.uk/research/statistics) 22 
leads to rapidly increasing costs (currently over US $1 trillion, estimated to reach $2 23 
trillion by 2030,3 to which BPSD have been shown to contribute over 25% of total 24 
indirect and 35% of total direct annual costs (i.e., $2,665 and $1,450 respectively in 25 
an individual patient) of care in an Israeli community setting.4 This may not be 26 
surprising as BPSD are ubiquitous, affecting < up to 90% of people during the course 27 
of dementia and strongly correlate with functional and cognitive impairment.5,6 They 28 
also cause family and carer partner distress, which predicts loss of independence,7 29 
early care home admission,8,9,10 higher use of emergency department11 and other 30 
health facilities;12 as well as requiring direct care4,13 in care facilities and the 31 
community.14 32 
loss of independence,13 and care home admission.4,14   33 
 34 
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The contribution of agitation to dementia costs has been reported to increase informal 1 
care costs in a homecare setting15 by 17% and increase overall costs16,17 by 22%. In 2 
care homes agitation accounts for 44% of excess costs on top of the costs of the home 3 
itself;18–20 indicating that calculated costs depend on the setting and increase in a 4 
dose–dependent manner with symptom severity (i.e., higher scores on the 5 
neuropsychiatric inventory (NPI); see also Herrmann21 and Gustavsson14 and 6 
colleagues).  7 
 8 
Evidence is accumulating that nonpharmacological (also known as psychosocial) 9 
interventions and person–centred care can reduce agitation and other behaviours.2,22  10 
Yet there are difficulties in sustaining implementation and change in practice beyond 11 
the period of the intervention.18 This is perhaps because implementing change takes 12 
practice and time, practice to bed in and additional support as these approaches are 13 
not built into the care environment. There may also be concerns about cost and staff 14 
time, driven by insufficient awareness of studies that have focused specifically on cost 15 
analysis ofing BPSD and demonstrated the potential savings that can be made by 16 
investing in treatments that are symptom targeted and individualised (i.e., person–17 
centred). Without a strong case for intervention– and cost–effectiveness, resistance 18 
to implementing change remains high, from managers and care workers at the local 19 
level, to policy makers, political leaders and societies at the macro–level. 20 
 21 
We reasoned that demonstration of cost–effectiveness could further incentivise 22 
governments, funders and service providers to invest in practice change and the 23 
implementation of effective person–centred approaches. We scoped reviewed the 24 
literature to calculate monetary costs of individual BPSD and their management, in 25 
order to determine whether there was evidence of financial benefits to convince policy 26 
makers and service providers to change practices to reduce BPSD. 27 
 28 
Nonpharmacological interventions for BPSD 29 
 30 
Nonpharmacological interventions, including well powered randomised controlled 31 
trials (RCTs), shown to be effective in reducing BPSD include: person–centred 32 
care,23–26 reminiscence–based approaches,27,28 aerobic and resistance exercise,29 33 
music,30,31 use of a robotic or soft seal,32,33 humour therapy,34,35 and educational 34 
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training.36,37 Specifically, person–centred care led to improvements in agitation 1 
revealed with the Cohen–Mansfield Agitation Inventory (CMAI) or Neuropsychiatric 2 
Inventory (NPI), reminiscence therapy improved apathy and depression measured 3 
using the Apathy Evaluation Scale (AES) and the Cornell Scale for Depression in 4 
Dementia (CSDD), and physical activity improved depression (determined with 5 
CSDD) and other BPSD (see Livingston and colleagues2).  6 
 7 
Barriers to adoption of these practices include the heterogeneity of interventions, the 8 
lack of rigour in their evaluation and concerns surrounding cost, resources and staff 9 
time. Cost–effectiveness analyses can illustrate how an outcome may (or may not) be 10 
desirable, despite what may otherwise be perceived as involving high costs. 11 
Simplistically this involves identifying the associated benefits of the intervention as well 12 
as the associated costs and subtracting the costs from the benefits. This approach is 13 
crucial (rather than focusing only on cost savings) given that to care effectively for 14 
people living with dementia and BPSD, competent and confident trained healthcare 15 
workers and adequate staff numbers are essential.  16 
 17 
Costing BPSD 18 
 19 
Cross–sectional, prospective and longitudinal studies have investigated costs of 20 
BPSD (usually agitation) and have used either group comparison approaches (i.e. 21 
based on dementia severity) or linear regression approaches to determine costs per 22 
unit increase on an individual symptom measure (see Table 1 for summary). Caution 23 
should be taken when interpreting findings from cross–sectional studies due to unclear 24 
causal mechanisms. We have focused primarily on prospective and longitudinal 25 
studies. Costs of BPSD differ between community, clinic, hospital and residential 26 
settings in line with differences in dependency levels and costs of care.38 Costs are 27 
generally calculated using used a general linear mixed model including relevant 28 
covariates to estimate main predictors of costs.  29 
 30 
In a 1–year prospective study of resource utilisation, a 1–point increase in agitation 31 
determined by the NPI resulted in an increase in costs of US$30 per month,21 where 32 
total cost of care was calculated to be US $1,298 per month. Other studies have 33 
reported between 1·6 – 17% increase in costs per 1–point increase on the total NPI in 34 
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a community setting.15,39–41 Some studies have considered variability and used 1 
standard deviations to compute costs where an increase of one standard deviation in 2 
NPI severity translated into a 6% and 8·8% increase in costs.14,38 While studies tend 3 
to focus on agitation, one study found apathy and hallucinations were the biggest 4 
contributors and significantly increased costs (p=0·0016 and p<0·0001 respectively).38 5 
 6 
Several intervention studies have calculated cost–effectiveness analyses in this area. 7 
In these, they calculated an incremental cost–effectiveness ratio (ICER). The ICER is 8 
calculated as the difference in total cost between two intervention groups, divided by 9 
the difference in outcome measures (e.g., agitation measured using CMAI or NPI) 10 
between the two intervention groups (see Table 2 for summary).25,32,42,43 ‘Willingness 11 
to pay’ for additional units of outcome has also been included in calculations to plot 12 
cost–effectiveness acceptability curves (CEACs)44 and determine if, from a societal 13 
perspective, an intervention is effective by leading to a clinically meaningful 14 
improvement in BPSD. For example, D’Amico and colleagues’ study calculated a 15 
clinically meaningful reduction in NPI (i.e., three points) to cost £1,263 and calculated 16 
a willingness to pay £500 per increment improvement (i.e., per 1–point decrease in 17 
NPI score) would mean the probability of exercise being cost–effective would be 18 
higher than 80 percent.45,46 19 
 20 
In a systematic review of worldwide studies costing individual BPSD18 the cost of 30 21 
interventions that had a significant impact on agitation was calculated, 11 of which 22 
used the CMAI. In total, health and social care costs in people without clinically 23 
significant symptoms in NPI agitation over three months were calculated to be around 24 
£7,000 compared to £15,000 for those with the most severe levels of agitation. The 25 
incremental cost per unit reduction in CMAI score following therapeutic activities was 26 
reported to be £162 for Montessori–based activities47 and £3,480 for a highly 27 
structured programme of sensorimotor activities.48 The cost per unit were calculated 28 
for music therapy49 at £4 and sensory interventions using acupressure50,47 at £24 and 29 
£143 respectively. Training paid caregivers in person–centred care or communication 30 
skills25,51,52 was costed at £6, £42 and £62 respectively per unit reduction in CMAI.  31 
 32 
The main health outcome measure used by the National Institute for Health and 33 
Clinical Excellence (NICE) and many other national reimbursement authorities is the 34 
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quality–adjusted life–year (QALY). A QALY is a unit that combines both quantity 1 
(length) of life and health–related quality of life into a single measure of health gain 2 
(NICE guidelines 2008,53 page 17). Cost–effectiveness is also often calculated 3 
considering improvements in quality of life. An RCT of an intervention to consider and 4 
address needs of residents with agitation and improve communication did not improve 5 
agitation but was cost–effective in improving quality of life.19 Livingston and 6 
colleagues18 measured cost–effectiveness as the mean QALYs gained per patient 7 
accrued to the intervention multiplied by the decision–makers’ maximum willingness 8 
to pay for a QALY, minus the mean incremental cost per patient for the intervention 9 
(termed net monetary benefits (NMBs)). This model converts the gain or loss in 10 
outcomes associated with the intervention into monetary units and subtracts the 11 
associated cost of the intervention to determine cost–effectiveness (NMB>0 12 
represents good value for money).  A willingness to pay £20,000 for a QALY (see UK 13 
NICE guidelines,53 page 18) equated to an 82 percent probability of being cost–14 
effective.18  QALYs are frequently used to access health outcomes and are used in 15 
calculating ICER, though have several limitations in the field of dementia research and 16 
the clinical relevance of quality of life measures (i.e., QALYs) has been questioned. 17 
 18 
Methodological inconsistencies and the techniques used to value informal care39 19 
make it difficult to compare findings across studies. Despite the variability in 20 
calculations and reporting approaches of symptom costs, all studies demonstrate 21 
that BPSD contribute significantly to the overall costs of dementia care. There is a 22 
general focus on agitation; costing of other symptoms is lacking apart from one study 23 
on apathy21 even though other symptoms such as apathy, anxiety and depression 24 
can cause significant distress,10 which would likely impact on costs. Several Other 25 
cost–effectiveness studies using person–centred and staff training approaches23,26 26 
55 have reported  cost–effectiveness though have not costed symptoms 27 
separately.26,54,56 alsoA UK study  found significant improvements in quality of life 28 
and BPSD in response topeople living with dementia following the intervention. 29 
person–centred approaches236,54 However, improvements in BPSD were not 30 
observed in people with young-onset dementia in a Dutch study; possibly due to 31 
overlap between the intervention and specialised methods of care already in use for 32 
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Time for action 1 
 2 
Barriers to achieving better value for money in dementia care include reluctance to 3 
implement evidence, poor coordination of health and social care provision and 4 
financing.5557 Evidence is presented of monetary costs of BPSD and of benefits of 5 
interventions. The few studies that have built cost–effectiveness analyses into their 6 
design indicate the economic feasibility of adopting non–pharmacological approaches 7 
such as person–centred care into everyday practice. This will require change in 8 
attitudes and care practice.  9 
  10 
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Table 1: Studies that have costed individual BPSD in different parts or the world. 
 









Setting, study type, 




BPSD cost ($ per 
unit or predictor %)  
Herrmann et al., 
2006, USA21 
Community setting.1–
year prospective study, 
N=500 
Agitation, NPI 1–point change 
associated with 
2·3% increase in 
total costs.  (1–point 
increase = $30 per 
month (95% CI: 
$19–$41) 






(Costs analysis, N= 
208) 
Agitation, NPI 1–point change 
associated with 8% 
increase in total 
costs 





Agitation, NPI 1–SD increase 
translated to 8% 
increase in costs 
(community setting) 
Lacey et al., 2013, 






Agitation, NPI 1–point change 
associated with 
1·62% increase in 
total costs 





Agitation, NPI 1–point change 
associated with 2% 
increase in informal 
costs 
Wübker et al., 2015, 





(community group ‘at 
risk’). Prospective 







translated to 8·8% 
increase in costs 
(community setting) 
 
Costa et al., 2018, 8 
European countries15 
Community (homecare) 






Agitation, NPI 17% increase in 
informal care costs 
(community setting) 
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Setting, study type, number 
of participants (N) 
BPSD, 
measure 




Residential setting, 2 
conditions: 21–day Inpatient 
Programme (IP) & 
Continuum of Care (CC) 
(21– vs. 7–days 
hospitalisation). N=178 
(N=68 & 110 respectively) 
Agitation, 
CMAI 
Change in CMAI score 
per US $1,000: CC: 0·89, 
IP: 0·27 (CC was more 
than three times more 
cost–effective) 
Chenoweth 
et al., 2009, 
Australia25 
Residential setting, 3 
conditions: Person–Centred 
Care (PCC), Dementia Care 
Mapping (DCM) and usual 
care. Cluster RCT, N=289 




Incremental cost per 1–
point decrease on CMAI 
scale. PCC: AU $8 AU, 
$6 at follow–up. DCC: AU 





Community setting, 2 
conditions: exercise and 
treatment as usual. RCT, 




Intervention cost: £284 
(range: £190–£320). 
CEAC: willingness to pay 
£500 per increment 
improvement, cost 
effective with a probability 





Residential setting, 3 
conditions: Therapeutic 
robotic seal (PARO), soft 
seal, usual care. Cluster 
RCT, N=415 (N=138, 140 
and 137 respectively) 
Agitation, 
CMAI 
AU $13 incremental cost 
per 1–point decrease on 
CMAI scale 
 
Abbreviations: CEAC, cost–effectiveness acceptability curve; CMAI, Cohen 
Mansfield agitation inventory; NPI, neuropsychiatric inventory. 
